首页 > 最新文献

Cardiovascular and Hematological Disorders - Drug Targets最新文献

英文 中文
Toxicity Evaluation of the Subacute Diazinon in Aged Male Rats: Hematological Aspects. 亚急性二嗪农对老年雄性大鼠的毒性评价:血液学方面。
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X20666200305103007
Saeed Samarghandian, Tahereh Farkhondeh, Shahnaz Yousefizadeh

Background & objective: Age-dependent Organophosphates (OPs) toxicity is a controversial topic. The present study was designed to investigate the effect of the sub-acute exposure to diazinon (DZN), one of the main OPs insecticides, on the hematological alterations in adult and aged male rats.

Methods: For the aim of this approach, the adult and aged rats were administered with DZN (15 mg/kg, orally) for 4 weeks. Then, the blood samples were collected from the retro-orbital sinus for measuring red blood cell (RBC), hemoglobin (Hb), hematocrit (Hct), platelets (PLT), MCV (mean corpuscular volume), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin (MCHC).

Results: The obtained results indicated that DZN significantly decreased RBCs (4.93 ± 0.41), Htc (28.12 ± 1.21), Hb (10.31 ± 0.36), MCHC (30.51 ± 2.04), MCV (62.86 ± 2.58), and PLT (265.6 ± 34.81) values in the adult and aged rats versus the age-matched control rats. Moreover, RBC, Hb, and Htc levels decreased significantly in the aged rats versus adult rats. However, no significant differences were observed between MCHC, MCV, and PLT levels in adult and aged rats. Moreover, the MCH concentration did not change in any group. Additionally, DZN did not deteriorate the hematological alterations in the aged rats versus adult rats.

Conclusion: the present study showed that the toxicity of DZN is not associated with age. However, more studies should be conducted to confirm this finding.

背景与目的:年龄依赖性有机磷(OPs)毒性是一个有争议的话题。本研究旨在探讨亚急性暴露于主要有机磷杀虫剂之一二嗪农(diazinon, DZN)对成年和老年雄性大鼠血液学的影响。方法:以成年大鼠和老年大鼠为研究对象,给予DZN (15 mg/kg,口服)4周。然后取眶后窦血,测定红细胞(RBC)、血红蛋白(Hb)、红细胞压积(Hct)、血小板(PLT)、平均红细胞体积(MCV)、平均红细胞血红蛋白(MCH)、平均红细胞血红蛋白(MCHC)。结果:与同龄对照组相比,DZN可显著降低成年和老年大鼠红细胞(4.93±0.41)、Htc(28.12±1.21)、Hb(10.31±0.36)、MCHC(30.51±2.04)、MCV(62.86±2.58)、PLT(265.6±34.81)值。此外,与成年大鼠相比,老年大鼠的RBC、Hb和Htc水平显著下降。然而,在成年大鼠和老年大鼠中,MCHC、MCV和PLT水平没有显著差异。各组MCH浓度无明显变化。此外,与成年大鼠相比,DZN没有恶化老年大鼠的血液学改变。结论:本研究表明,DZN的毒性与年龄无关。然而,需要进行更多的研究来证实这一发现。
{"title":"Toxicity Evaluation of the Subacute Diazinon in Aged Male Rats: Hematological Aspects.","authors":"Saeed Samarghandian,&nbsp;Tahereh Farkhondeh,&nbsp;Shahnaz Yousefizadeh","doi":"10.2174/1871529X20666200305103007","DOIUrl":"https://doi.org/10.2174/1871529X20666200305103007","url":null,"abstract":"<p><strong>Background & objective: </strong>Age-dependent Organophosphates (OPs) toxicity is a controversial topic. The present study was designed to investigate the effect of the sub-acute exposure to diazinon (DZN), one of the main OPs insecticides, on the hematological alterations in adult and aged male rats.</p><p><strong>Methods: </strong>For the aim of this approach, the adult and aged rats were administered with DZN (15 mg/kg, orally) for 4 weeks. Then, the blood samples were collected from the retro-orbital sinus for measuring red blood cell (RBC), hemoglobin (Hb), hematocrit (Hct), platelets (PLT), MCV (mean corpuscular volume), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin (MCHC).</p><p><strong>Results: </strong>The obtained results indicated that DZN significantly decreased RBCs (4.93 ± 0.41), Htc (28.12 ± 1.21), Hb (10.31 ± 0.36), MCHC (30.51 ± 2.04), MCV (62.86 ± 2.58), and PLT (265.6 ± 34.81) values in the adult and aged rats versus the age-matched control rats. Moreover, RBC, Hb, and Htc levels decreased significantly in the aged rats versus adult rats. However, no significant differences were observed between MCHC, MCV, and PLT levels in adult and aged rats. Moreover, the MCH concentration did not change in any group. Additionally, DZN did not deteriorate the hematological alterations in the aged rats versus adult rats.</p><p><strong>Conclusion: </strong>the present study showed that the toxicity of DZN is not associated with age. However, more studies should be conducted to confirm this finding.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 3","pages":"198-201"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/a4/CHDDT-20-198.PMC8388065.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37707695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Antihyperglycemic Potential of Matricaria pubescens (Desf.) Schultz. in Streptozotocin-induced Diabetic Rats. 毛蕊草的抗高血糖潜能舒尔茨。链脲佐菌素诱导的糖尿病大鼠。
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X20666200630112610
Ayoub Amssayef, Mohammed Ajebli, Mohamed Eddouks

Aims: The study aimed to investigate the antihyperglycemic activity of Matricaria pubescens.

Background: Matricaria pubescens (Def). Shultz (Asteraceae) is commonly used traditionally for the treatment of diabetes in Morocco.

Objective: The present investigation aimed to assess the antihyperglycemic and antioxidant effects of the aqueous extract of the aerial part of Matricaria pubescens (M. pubescens).

Methods: The effect of a single and repeated oral administration of the aqueous extract of aerial part of M. pubescens (AEAPMP) at a dose of 40 mg/kg on glucose was examined in normal and streptozotocin-induced diabetic rats. Additionally, histopathological examination of the pancreas and liver was carried out according to the Hematoxylin-Eosin method. The antioxidant activity was performed using the DPPH assay.

Results: The results showed that the aqueous extract of M. pubescens (AEAPMP) exhibited a significant lowering activity on blood glucose levels in STZ-induced diabetic rats. In addition, AEAPMP ameliorated the histopathological tissues of the liver and pancreas. Furthermore, in vitro antioxidant activity of AEAPMP has been shown.

Conclusion: In conclusion, this study demonstrates that M. pubescens possesses a beneficial effect against hyperglycemia associated with diabetes.

目的:研究毛蕊草的降血糖作用。背景:母羊属植物(Def)。Shultz(菊科)在摩洛哥传统上通常用于治疗糖尿病。目的:研究短毛母草(M. pubescens)地上部水提物的降血糖和抗氧化作用。方法:分别以40 mg/kg剂量单次和多次口服短毛藤气部水提物(AEAPMP)对正常和链脲佐菌素诱导的糖尿病大鼠血糖的影响。胰、肝按苏木精-伊红法行组织病理学检查。采用DPPH法测定其抗氧化活性。结果:毛茛水提物(AEAPMP)对stz诱导的糖尿病大鼠血糖水平有明显的降低作用。此外,AEAPMP改善了肝脏和胰腺的组织病理组织。此外,AEAPMP还具有体外抗氧化活性。结论:综上所述,本研究证明毛蕊支原体对糖尿病相关高血糖具有有益作用。
{"title":"Antihyperglycemic Potential of Matricaria pubescens (Desf.) Schultz. in Streptozotocin-induced Diabetic Rats.","authors":"Ayoub Amssayef,&nbsp;Mohammed Ajebli,&nbsp;Mohamed Eddouks","doi":"10.2174/1871529X20666200630112610","DOIUrl":"https://doi.org/10.2174/1871529X20666200630112610","url":null,"abstract":"<p><strong>Aims: </strong>The study aimed to investigate the antihyperglycemic activity of Matricaria pubescens.</p><p><strong>Background: </strong>Matricaria pubescens (Def). Shultz (Asteraceae) is commonly used traditionally for the treatment of diabetes in Morocco.</p><p><strong>Objective: </strong>The present investigation aimed to assess the antihyperglycemic and antioxidant effects of the aqueous extract of the aerial part of Matricaria pubescens (M. pubescens).</p><p><strong>Methods: </strong>The effect of a single and repeated oral administration of the aqueous extract of aerial part of M. pubescens (AEAPMP) at a dose of 40 mg/kg on glucose was examined in normal and streptozotocin-induced diabetic rats. Additionally, histopathological examination of the pancreas and liver was carried out according to the Hematoxylin-Eosin method. The antioxidant activity was performed using the DPPH assay.</p><p><strong>Results: </strong>The results showed that the aqueous extract of M. pubescens (AEAPMP) exhibited a significant lowering activity on blood glucose levels in STZ-induced diabetic rats. In addition, AEAPMP ameliorated the histopathological tissues of the liver and pancreas. Furthermore, in vitro antioxidant activity of AEAPMP has been shown.</p><p><strong>Conclusion: </strong>In conclusion, this study demonstrates that M. pubescens possesses a beneficial effect against hyperglycemia associated with diabetes.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 4","pages":"297-304"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38106153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials. 比伐鲁定与肝素在急性冠脉综合征干预中的比较:随机试验的系统综述。
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X19666190626124057
Sukhdeep Bhogal, Debabrata Mukherjee, Jayant Bagai, Huu T Truong, Hemang B Panchal, Ghulam Murtaza, Mustafa Zaman, Rajesh Sachdeva, Timir K Paul

Introduction: Bivalirudin and heparin are the two most commonly used anticoagulants used during Percutaneous Coronary Intervention (PCI). The results of Randomized Controlled Trials (RCTs) comparing bivalirudin versus heparin monotherapy in the era of radial access are controversial, questioning the positive impact of bivalirudin on bleeding. The purpose of this systematic review is to summarize the results of RCTs comparing the efficacy and safety of bivalirudin versus heparin with or without Glycoprotein IIb/IIIa Inhibitors (GPI).

Methods: This systematic review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA statements for reporting systematic reviews. We searched the National Library of Medicine PubMed, Clinicaltrial.gov and the Cochrane Central Register of Controlled Trials to include clinical studies comparing bivalirudin with heparin in patients undergoing PCI. Sixteen studies met inclusion criteria and were reviewed for the summary.

Findings: Several RCTs and meta-analyses have demonstrated the superiority of bivalirudin over heparin plus routine GPI use in terms of preventing bleeding complications but at the expense of increased risk of ischemic complications such as stent thrombosis. The hypothesis of post- PCI bivalirudin infusion to mitigate the risk of acute stent thrombosis has been tested in various RCTs with conflicting results. In comparison, heparin offers the advantage of having a reversible agent, of lower cost and reduced incidence of ischemic complications.

Conclusion: Bivalirudin demonstrates its superiority over heparin plus GPI with better clinical outcomes in terms of less bleeding complications, thus making it as anticoagulation of choice particularly in patients at high risk of bleeding. Further studies are warranted for head to head comparison of bivalirudin to heparin monotherapy to establish an optimal heparin dosing regimen and post-PCI bivalirudin infusion to affirm its beneficial effect in reducing acute stent thrombosis.

简介:比伐鲁定和肝素是经皮冠状动脉介入治疗(PCI)中最常用的两种抗凝剂。在桡动脉通路时代,比较比伐鲁定与肝素单药治疗的随机对照试验(RCTs)结果存在争议,质疑比伐鲁定对出血的积极影响。本系统综述的目的是总结比较比伐鲁定与肝素联合或不联合使用糖蛋白IIb/IIIa抑制剂(GPI)的疗效和安全性的随机对照试验的结果。方法:本系统评价按照系统评价首选报告项目和meta分析PRISMA报告系统评价声明进行。我们检索了国家医学图书馆PubMed、Clinicaltrial.gov和Cochrane中央对照试验注册库,以纳入比伐鲁定与肝素在PCI患者中的临床比较研究。16项研究符合纳入标准,并进行了综述。研究结果:几项随机对照试验和荟萃分析表明,在预防出血并发症方面,比伐鲁定优于肝素加常规GPI,但代价是缺血性并发症(如支架血栓形成)的风险增加。PCI术后输注比伐鲁定可降低急性支架血栓形成风险的假设已在各种随机对照试验中得到验证,但结果相互矛盾。相比之下,肝素具有可逆性、成本较低和减少缺血性并发症发生率的优势。结论:比伐鲁定优于肝素加GPI,出血并发症少,临床效果好,是高危出血患者抗凝治疗的首选。需要进一步研究比伐鲁定与肝素单药治疗的头对头比较,以建立最佳肝素给药方案和pci后比伐鲁定输注,以确认其在减少急性支架血栓形成方面的有益作用。
{"title":"Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials.","authors":"Sukhdeep Bhogal,&nbsp;Debabrata Mukherjee,&nbsp;Jayant Bagai,&nbsp;Huu T Truong,&nbsp;Hemang B Panchal,&nbsp;Ghulam Murtaza,&nbsp;Mustafa Zaman,&nbsp;Rajesh Sachdeva,&nbsp;Timir K Paul","doi":"10.2174/1871529X19666190626124057","DOIUrl":"https://doi.org/10.2174/1871529X19666190626124057","url":null,"abstract":"<p><strong>Introduction: </strong>Bivalirudin and heparin are the two most commonly used anticoagulants used during Percutaneous Coronary Intervention (PCI). The results of Randomized Controlled Trials (RCTs) comparing bivalirudin versus heparin monotherapy in the era of radial access are controversial, questioning the positive impact of bivalirudin on bleeding. The purpose of this systematic review is to summarize the results of RCTs comparing the efficacy and safety of bivalirudin versus heparin with or without Glycoprotein IIb/IIIa Inhibitors (GPI).</p><p><strong>Methods: </strong>This systematic review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA statements for reporting systematic reviews. We searched the National Library of Medicine PubMed, Clinicaltrial.gov and the Cochrane Central Register of Controlled Trials to include clinical studies comparing bivalirudin with heparin in patients undergoing PCI. Sixteen studies met inclusion criteria and were reviewed for the summary.</p><p><strong>Findings: </strong>Several RCTs and meta-analyses have demonstrated the superiority of bivalirudin over heparin plus routine GPI use in terms of preventing bleeding complications but at the expense of increased risk of ischemic complications such as stent thrombosis. The hypothesis of post- PCI bivalirudin infusion to mitigate the risk of acute stent thrombosis has been tested in various RCTs with conflicting results. In comparison, heparin offers the advantage of having a reversible agent, of lower cost and reduced incidence of ischemic complications.</p><p><strong>Conclusion: </strong>Bivalirudin demonstrates its superiority over heparin plus GPI with better clinical outcomes in terms of less bleeding complications, thus making it as anticoagulation of choice particularly in patients at high risk of bleeding. Further studies are warranted for head to head comparison of bivalirudin to heparin monotherapy to establish an optimal heparin dosing regimen and post-PCI bivalirudin infusion to affirm its beneficial effect in reducing acute stent thrombosis.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 1","pages":"3-15"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1871529X19666190626124057","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37103951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
An HHV-8 Positive HIV Negative Multicentric Castleman's Disease, who Responded well to Rituximab Alone. 一个HHV-8阳性HIV阴性多中心Castleman病,单独使用利妥昔单抗反应良好。
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X19666190227185318
Dimitris Kounatidis, Dimitra Rontogianni, Dimitrios Sampaziotis, Maria Vardaka, Chara Giatra, Christodoulos Dolapsakis, Evangelia Margellou, Natalia G Vallianou

Background: Multicentric Castleman Disease (MCD) presents with enlarged lymph nodes in multiple regions and systemic inflammatory symptoms, due to the dysregulation of cytokines, most commonly interleukin-6 (IL-6). Human herpes virus-8 (HHV-8) is strongly related to MCD (HHV-8-associated MCD) and is being implicated in cytokine dysregulation in patients, the majority of whom are HIV positive or immunosuppressed. Preferred treatment of HHV-8- associated MCD depends on the presence or not of concurrent Kaposi sarcoma and on whether the patient has life-threatening organ failure or poor performance status thought to be related to HHV- 8-associated MCD.

Case presentation: Herein, we describe a female patient with HHV-8 positive, HIV negative MCD, who responded well to the administration of rituximab once weekly for four weeks alone for three cycles.

Conclusion: HHV-8 positive, HIV negative MCD treatment modalities are only anecdotal due to the rarity of this form of MCD. Administration of rituximab alone seems to be beneficial among patients with good performance status and the absence of life-threatening organ failure in cases of HHV-8 positive, HIV negative MCD.

背景:多中心Castleman病(MCD)由于细胞因子,最常见的是白细胞介素-6 (IL-6)的失调,表现为多区域淋巴结肿大和全身性炎症症状。人类疱疹病毒-8 (HHV-8)与MCD (HHV-8相关的MCD)密切相关,并与患者的细胞因子失调有关,其中大多数患者是HIV阳性或免疫抑制。HHV-8相关MCD的首选治疗取决于是否存在并发卡波西肉瘤,以及患者是否有危及生命的器官衰竭或被认为与HHV-8相关MCD相关的表现不佳状态。病例介绍:在这里,我们描述了一位患有HHV-8阳性,HIV阴性MCD的女性患者,她对每周一次的利妥昔单抗治疗有良好的反应,持续4周,共3个周期。结论:HHV-8阳性,HIV阴性的MCD治疗方式只是传闻,因为这种形式的MCD很罕见。在HHV-8阳性、HIV阴性的MCD患者中,单纯使用利妥昔单抗似乎是有益的,这些患者表现良好,没有危及生命的器官衰竭。
{"title":"An HHV-8 Positive HIV Negative Multicentric Castleman's Disease, who Responded well to Rituximab Alone.","authors":"Dimitris Kounatidis,&nbsp;Dimitra Rontogianni,&nbsp;Dimitrios Sampaziotis,&nbsp;Maria Vardaka,&nbsp;Chara Giatra,&nbsp;Christodoulos Dolapsakis,&nbsp;Evangelia Margellou,&nbsp;Natalia G Vallianou","doi":"10.2174/1871529X19666190227185318","DOIUrl":"https://doi.org/10.2174/1871529X19666190227185318","url":null,"abstract":"<p><strong>Background: </strong>Multicentric Castleman Disease (MCD) presents with enlarged lymph nodes in multiple regions and systemic inflammatory symptoms, due to the dysregulation of cytokines, most commonly interleukin-6 (IL-6). Human herpes virus-8 (HHV-8) is strongly related to MCD (HHV-8-associated MCD) and is being implicated in cytokine dysregulation in patients, the majority of whom are HIV positive or immunosuppressed. Preferred treatment of HHV-8- associated MCD depends on the presence or not of concurrent Kaposi sarcoma and on whether the patient has life-threatening organ failure or poor performance status thought to be related to HHV- 8-associated MCD.</p><p><strong>Case presentation: </strong>Herein, we describe a female patient with HHV-8 positive, HIV negative MCD, who responded well to the administration of rituximab once weekly for four weeks alone for three cycles.</p><p><strong>Conclusion: </strong>HHV-8 positive, HIV negative MCD treatment modalities are only anecdotal due to the rarity of this form of MCD. Administration of rituximab alone seems to be beneficial among patients with good performance status and the absence of life-threatening organ failure in cases of HHV-8 positive, HIV negative MCD.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 1","pages":"84-86"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1871529X19666190227185318","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37179169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Co-existence of Follicular Lymphoma in the Lymph Node with High-grade B Cell Lymphoma in the Bone Marrow of a Patient with Spontaneous Tumor Lysis Syndrome. 淋巴结滤泡性淋巴瘤与骨髓高级别B细胞淋巴瘤共存的一例自发性肿瘤溶解综合征患者
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X20666200130095417
Chara Giatra, Alexandros G Sykaras, Fotis Constantinou, Victoria Gennimata, Dimitrios Sampaziotis, Eleni Geladari, Dimitris Kounatidis, Natalia G Vallianou

A significant percentage of B-cell lymphomas are characterized by bone marrow involvement (BMI) at diagnosis. In most cases, there is a concordance between the type of lymphoma present in the lymph node and the lymphoma present in the bone marrow. Herein, we presented a sixty-seven years old female patient, who was diagnosed with High-Grade B-cell Lymphoma (HGBL) in the bone marrow, while simultaneously, in the peripheral lymph node, the presence of Follicular Lymphoma (FL) was noted. The patient was presented to the hospital with spontaneous tumor lysis syndrome, a finding compatible with the aggressive course of the HGBL. To our knowledge, this is the first case of the co-existence of HGBL in the bone marrow and FL in a lymph node, which might be attributed to merely a coincidence or to the transformation of the cells in the preferable milieu of the bone marrow.

相当比例的b细胞淋巴瘤在诊断时以骨髓受累(BMI)为特征。在大多数情况下,存在于淋巴结的淋巴瘤类型和存在于骨髓的淋巴瘤类型是一致的。在此,我们报告了一位67岁的女性患者,她被诊断为骨髓高级别b细胞淋巴瘤(HGBL),同时,在周围淋巴结,发现了滤泡性淋巴瘤(FL)的存在。该患者因自发性肿瘤溶解综合征被送到医院,这一发现与HGBL的侵袭性病程相符。据我们所知,这是骨髓中HGBL和淋巴结中FL共存的第一例,这可能仅仅是巧合,也可能是骨髓中细胞在较好的环境中发生了转化。
{"title":"Co-existence of Follicular Lymphoma in the Lymph Node with High-grade B Cell Lymphoma in the Bone Marrow of a Patient with Spontaneous Tumor Lysis Syndrome.","authors":"Chara Giatra,&nbsp;Alexandros G Sykaras,&nbsp;Fotis Constantinou,&nbsp;Victoria Gennimata,&nbsp;Dimitrios Sampaziotis,&nbsp;Eleni Geladari,&nbsp;Dimitris Kounatidis,&nbsp;Natalia G Vallianou","doi":"10.2174/1871529X20666200130095417","DOIUrl":"https://doi.org/10.2174/1871529X20666200130095417","url":null,"abstract":"<p><p>A significant percentage of B-cell lymphomas are characterized by bone marrow involvement (BMI) at diagnosis. In most cases, there is a concordance between the type of lymphoma present in the lymph node and the lymphoma present in the bone marrow. Herein, we presented a sixty-seven years old female patient, who was diagnosed with High-Grade B-cell Lymphoma (HGBL) in the bone marrow, while simultaneously, in the peripheral lymph node, the presence of Follicular Lymphoma (FL) was noted. The patient was presented to the hospital with spontaneous tumor lysis syndrome, a finding compatible with the aggressive course of the HGBL. To our knowledge, this is the first case of the co-existence of HGBL in the bone marrow and FL in a lymph node, which might be attributed to merely a coincidence or to the transformation of the cells in the preferable milieu of the bone marrow.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 3","pages":"237-240"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37593531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antihyperglycemic Activity and Safety Assessment of the Aqueous Extract of Aerial Parts of Scorzonera undulata ssp deliciosa in Rat. 山葵地上部位水提物对大鼠的降糖活性及安全性评价。
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X20666200827113029
Mohammed Ajebli, Ayoub Amssayef, Mohamed Eddouks

Aims: The aim of this study was to evaluate the antidiabetic effect of Scorzonera undulata.

Background: Scorzonera undulata ssp deliciosa, locally known as "Guiz", is used as a phytomedicine in Morocco and Algeria to treat different health problems. Interestingly, it is used in the Moroccan pharmacopeia to treat diabetes. To our knowledge, this medicinal herb has never been investigated for any pharmacological activity.

Objective: This study aimed to evaluate the antihyperglycemic effect of the aqueous extract of the aerial part of Scorzonera undulata (SUAP) in normal and STZ-induced diabetic rats and to assess the acute toxicity of this extract in Wistar rats.

Methods: This study investigated the effects of SUAP at a dose of 20 mg/kg on blood glucose levels in normal and streptozotocin(STZ)-induced diabetic rats. The acute toxicity of SUAP was examined according to the OECD test guideline; rats were divided into four groups of each sex and orally received the SUAP (1000, 2000, or 3000 mg/kg BW). Post-treatment, body weight, signs of toxicity, and/or mortality were observed during 14 days. Other assays such as histopathological examination, preliminary phytochemical investigation, determination of glycogen content and evaluation of α-amylase were performed according to standard protocols.

Results: The findings of the current study depicted that both single and repeated oral administration of SUAP (20 mg/kg) generated a significant fall in the blood glucose levels in diabetic rats. A single oral administration of SUAP (at the highest dose of 3000 mg/kg BW) had no significant acute toxicological effects, and oral LD50 of SUAP was greater than 3000 mg/kg. Furthermore, repeated oral administration of SUAP during 15 days led to an increase in the liver glycogen content in diabetic rats to improve the histopathological structure of the liver and pancreas in SUAPtreated diabetic rats and to ameliorate some biochemical parameters such as ALT and creatinine. SUAP had no effect on α-amylase activity. In addition, the preliminary phytochemical investigation showed the richness of the roots of SUAP in some phytochemicals, particularly the polyphenols.

Conclusion: The present study demonstrates the antihyperglycemic effect of Scorzonera undulata in diabetic rats which could be involved through the improvement of liver structure and function. In addition, the dose used is not toxic. Finally, the extract contains large amounts of bioactive compounds, mainly polyphenols.

目的:探讨山葵的降糖作用。背景:山葵在摩洛哥和阿尔及利亚被用作植物药来治疗不同的健康问题,在当地被称为"Guiz"。有趣的是,摩洛哥药典用它来治疗糖尿病。据我们所知,这种草药从未被研究过任何药理活性。目的:研究波纹天蝎空中部分水提物对正常及stz诱导的糖尿病大鼠的降糖作用,并评价该水提物对Wistar大鼠的急性毒性。方法:研究20 mg/kg剂量的SUAP对正常及STZ诱导的糖尿病大鼠血糖水平的影响。按照OECD试验指南检测SUAP的急性毒性;将大鼠分为雌雄四组,分别口服SUAP(1000、2000、3000 mg/kg BW)。在14天内观察治疗后的体重、毒性体征和/或死亡率。其他试验如组织病理学检查、初步植物化学调查、糖原含量测定和α-淀粉酶评价等均按标准方案进行。结果:本研究结果表明,单次和多次口服SUAP (20mg /kg)均可显著降低糖尿病大鼠的血糖水平。单次口服SUAP(最高剂量为3000 mg/kg BW)无明显急性毒理学效应,且口服LD50大于3000 mg/kg。此外,连续15天多次口服SUAP可提高糖尿病大鼠肝糖原含量,改善糖尿病大鼠肝脏和胰腺的组织病理结构,改善ALT和肌酐等生化指标。SUAP对α-淀粉酶活性无影响。此外,初步的植物化学研究表明,SUAP根中的一些植物化学物质,特别是多酚含量丰富。结论:山葵对糖尿病大鼠的降血糖作用可能与改善肝脏结构和功能有关。此外,所使用的剂量是无毒的。最后,提取物含有大量的生物活性化合物,主要是多酚。
{"title":"Antihyperglycemic Activity and Safety Assessment of the Aqueous Extract of Aerial Parts of Scorzonera undulata ssp deliciosa in Rat.","authors":"Mohammed Ajebli,&nbsp;Ayoub Amssayef,&nbsp;Mohamed Eddouks","doi":"10.2174/1871529X20666200827113029","DOIUrl":"https://doi.org/10.2174/1871529X20666200827113029","url":null,"abstract":"<p><strong>Aims: </strong>The aim of this study was to evaluate the antidiabetic effect of Scorzonera undulata.</p><p><strong>Background: </strong>Scorzonera undulata ssp deliciosa, locally known as \"Guiz\", is used as a phytomedicine in Morocco and Algeria to treat different health problems. Interestingly, it is used in the Moroccan pharmacopeia to treat diabetes. To our knowledge, this medicinal herb has never been investigated for any pharmacological activity.</p><p><strong>Objective: </strong>This study aimed to evaluate the antihyperglycemic effect of the aqueous extract of the aerial part of Scorzonera undulata (SUAP) in normal and STZ-induced diabetic rats and to assess the acute toxicity of this extract in Wistar rats.</p><p><strong>Methods: </strong>This study investigated the effects of SUAP at a dose of 20 mg/kg on blood glucose levels in normal and streptozotocin(STZ)-induced diabetic rats. The acute toxicity of SUAP was examined according to the OECD test guideline; rats were divided into four groups of each sex and orally received the SUAP (1000, 2000, or 3000 mg/kg BW). Post-treatment, body weight, signs of toxicity, and/or mortality were observed during 14 days. Other assays such as histopathological examination, preliminary phytochemical investigation, determination of glycogen content and evaluation of α-amylase were performed according to standard protocols.</p><p><strong>Results: </strong>The findings of the current study depicted that both single and repeated oral administration of SUAP (20 mg/kg) generated a significant fall in the blood glucose levels in diabetic rats. A single oral administration of SUAP (at the highest dose of 3000 mg/kg BW) had no significant acute toxicological effects, and oral LD50 of SUAP was greater than 3000 mg/kg. Furthermore, repeated oral administration of SUAP during 15 days led to an increase in the liver glycogen content in diabetic rats to improve the histopathological structure of the liver and pancreas in SUAPtreated diabetic rats and to ameliorate some biochemical parameters such as ALT and creatinine. SUAP had no effect on α-amylase activity. In addition, the preliminary phytochemical investigation showed the richness of the roots of SUAP in some phytochemicals, particularly the polyphenols.</p><p><strong>Conclusion: </strong>The present study demonstrates the antihyperglycemic effect of Scorzonera undulata in diabetic rats which could be involved through the improvement of liver structure and function. In addition, the dose used is not toxic. Finally, the extract contains large amounts of bioactive compounds, mainly polyphenols.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 4","pages":"305-316"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38322420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Evaluation of Toxicity and Antihyperlipidemic Activity of Spondias Mombin l. Leaves Methanolic Extract in Laboratory Rats. 海棘叶甲醇提取物对实验大鼠的毒性及降血脂活性评价。
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X20999201027232556
Mayur Porwal, Sandeep K Gautam, Najam A Khan, Kamal K Maheshwari

Aims: To study the toxicological profile and anti-hyperlipidemic effects of Spondias mombin leaves methanolic extract in experimental rats.

Background: Preventing high levels of lipids or its recurrence is currently one of the key aims of clinical and experimental studies.

Objective: This study was carried out to investigate the toxicological profile and anti-hyperlipidemic effects of methanolic extract of leaves of Spondias mombin.

Methods: The acute toxicity study was carried out where the limited dose of 2000 mg/kg body weight was administered to five rats at 48 h intervals. The interpretation was prepared and recorded for 24 h. In the sub-acute toxicity study, rats were treated with 250, 500, and 1000 mg/kg doses of the extract every 24 h for 28 days. The hematological, biochemical, and histopathological tests of treated animals were carried out at the end of the test. The anti-hyperlipidemic activity of plant extract (100, 200 mg/kg) was studied on Triton-X-100 induced hyperlipidemia in rats. Histopathological changes in the liver of rats were examined.

Results: For acute and subacute treatment, the extract did not reveal any signs of toxicity or mortality, or any significant effects on hematological, biochemical parameters, and histopathology of organs. The extract demonstrated an important anti-hyperlipidemic result by decreasing the serum levels of cholesterol, TGs, LDL, VLDL, and enhancing HDL.

Conclusion: Taking up the evidence of the experimental study, we can conclude that the methanolic extract of Spondias mombin leaves helps in declining hyperlipidemia in rats and it can be safely used for a period of 28 days to treat hyperlipidemia.

目的:研究海棘叶甲醇提取物对实验大鼠的毒理学特征及抗高血脂作用。背景:预防高血脂或其复发是目前临床和实验研究的主要目的之一。目的:研究海棘叶甲醇提取物的毒理学特征及抗高脂血症作用。方法:5只大鼠按2000 mg/kg体重限定剂量,间隔48 h进行急性毒性研究。在亚急性毒性研究中,大鼠每24小时分别给予250、500和1000 mg/kg剂量的提取物,持续28天。试验结束时对处理动物进行血液学、生化和组织病理学检查。研究植物提取物(100、200 mg/kg)对Triton-X-100诱导的高脂血症大鼠的抗高脂血症活性。观察大鼠肝脏组织病理学变化。结果:在急性和亚急性治疗中,提取物未显示出任何毒性或死亡迹象,对血液、生化参数和器官组织病理学无明显影响。该提取物通过降低血清胆固醇、tg、LDL、VLDL水平和提高HDL水平显示出重要的抗高脂血症效果。结论:结合实验研究的证据,我们可以得出,海棘叶甲醇提取物具有降低大鼠高脂血症的作用,并且可以安全使用28天治疗高脂血症。
{"title":"Evaluation of Toxicity and Antihyperlipidemic Activity of Spondias Mombin l. Leaves Methanolic Extract in Laboratory Rats.","authors":"Mayur Porwal,&nbsp;Sandeep K Gautam,&nbsp;Najam A Khan,&nbsp;Kamal K Maheshwari","doi":"10.2174/1871529X20999201027232556","DOIUrl":"https://doi.org/10.2174/1871529X20999201027232556","url":null,"abstract":"<p><strong>Aims: </strong>To study the toxicological profile and anti-hyperlipidemic effects of Spondias mombin leaves methanolic extract in experimental rats.</p><p><strong>Background: </strong>Preventing high levels of lipids or its recurrence is currently one of the key aims of clinical and experimental studies.</p><p><strong>Objective: </strong>This study was carried out to investigate the toxicological profile and anti-hyperlipidemic effects of methanolic extract of leaves of Spondias mombin.</p><p><strong>Methods: </strong>The acute toxicity study was carried out where the limited dose of 2000 mg/kg body weight was administered to five rats at 48 h intervals. The interpretation was prepared and recorded for 24 h. In the sub-acute toxicity study, rats were treated with 250, 500, and 1000 mg/kg doses of the extract every 24 h for 28 days. The hematological, biochemical, and histopathological tests of treated animals were carried out at the end of the test. The anti-hyperlipidemic activity of plant extract (100, 200 mg/kg) was studied on Triton-X-100 induced hyperlipidemia in rats. Histopathological changes in the liver of rats were examined.</p><p><strong>Results: </strong>For acute and subacute treatment, the extract did not reveal any signs of toxicity or mortality, or any significant effects on hematological, biochemical parameters, and histopathology of organs. The extract demonstrated an important anti-hyperlipidemic result by decreasing the serum levels of cholesterol, TGs, LDL, VLDL, and enhancing HDL.</p><p><strong>Conclusion: </strong>Taking up the evidence of the experimental study, we can conclude that the methanolic extract of Spondias mombin leaves helps in declining hyperlipidemia in rats and it can be safely used for a period of 28 days to treat hyperlipidemia.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 4","pages":"289-296"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38538675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Association between Serum Vitamin D Level and Echocardiographic Abnormalities in Patients with Thalassemia Major. 重度地中海贫血患者血清维生素D水平与超声心动图异常的关系。
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X20666200701104931
Mehdi Pishgahi, Mahtab Niroomand, Rama Bozorgmehr, Shirin Ghane-Fard, Farideh Mousavi, Mohammadreza Tabary, Isa Khaheshi

Objectives: Thalassemia major (TM) is one of the most common blood disorders with a high mortality rate due to cardiovascular disease. Vitamin D deficiency has been suggested to implicate in cardiac abnormalities. In this prospective study, we aimed to investigate the relationship between serum levels of vitamin D and tissue Doppler (TD) echocardiographic indices in thalassemia major patients.

Methods: A total of 81 TM patients, including 56 females and 25 males, with a mean age of 27.5± 6.8 years, were enrolled consecutively. Serum levels of vitamin D and other biomedical parameters were measured. Then, all patients were subjected to TD echocardiography. Correlations between the serum parameters and systolic and diastolic indices were examined.

Results: The serum level of vitamin D was correlated with systolic and diastolic indices such as the EF (r= 0.33, P= 0.003) and TD Imaging (TDI)-lateral (r= 0.31, P= 0.005). However, no correlations were observed between vitamin D deficiency and the LV septal and posterior wall thickness, TDIseptal, tricuspid regurgitation peak gradient (TRPG), pulmonary artery systolic pressure (PASP), deceleration time (DT), and propagation velocity (PVcm/s) indices. The results revealed also no linear correlations between serum vitamin D and albumin (r= -0.17, P= 0.06), ALP (r= -0.12, P= 0.14), T4 (r= -0.11, P= 0.16), as well as TSH (r= -0.10, P= 0.19).

Conclusion: It seems that vitamin D deficiency in patients with TM is associated with systolic but not diastolic dysfunctions, possibly as consequences of related biochemical abnormalities.

目的:地中海贫血(TM)是最常见的血液疾病之一,由心血管疾病引起,死亡率高。维生素D缺乏被认为与心脏异常有关。在这项前瞻性研究中,我们旨在探讨地中海贫血重症患者血清维生素D水平与组织多普勒(TD)超声心动图指标的关系。方法:共纳入81例TM患者,其中女性56例,男性25例,平均年龄27.5±6.8岁。测定血清维生素D水平及其他生物医学参数。然后,所有患者均接受TD超声心动图检查。检查血清参数与收缩期和舒张期指标的相关性。结果:血清维生素D水平与EF (r= 0.33, P= 0.003)、TDI (r= 0.31, P= 0.005)等收缩期和舒张期指标相关。然而,维生素D缺乏与左室间隔和后壁厚度、TDIseptal、三尖瓣反流峰梯度(TRPG)、肺动脉收缩压(PASP)、减速时间(DT)和传播速度(PVcm/s)指标无相关性。结果还显示血清维生素D与白蛋白(r= -0.17, P= 0.06)、ALP (r= -0.12, P= 0.14)、T4 (r= -0.11, P= 0.16)和TSH (r= -0.10, P= 0.19)之间无线性相关。结论:TM患者的维生素D缺乏似乎与收缩期功能障碍有关,而与舒张期功能障碍无关,可能是相关生化异常的结果。
{"title":"Association between Serum Vitamin D Level and Echocardiographic Abnormalities in Patients with Thalassemia Major.","authors":"Mehdi Pishgahi,&nbsp;Mahtab Niroomand,&nbsp;Rama Bozorgmehr,&nbsp;Shirin Ghane-Fard,&nbsp;Farideh Mousavi,&nbsp;Mohammadreza Tabary,&nbsp;Isa Khaheshi","doi":"10.2174/1871529X20666200701104931","DOIUrl":"https://doi.org/10.2174/1871529X20666200701104931","url":null,"abstract":"<p><strong>Objectives: </strong>Thalassemia major (TM) is one of the most common blood disorders with a high mortality rate due to cardiovascular disease. Vitamin D deficiency has been suggested to implicate in cardiac abnormalities. In this prospective study, we aimed to investigate the relationship between serum levels of vitamin D and tissue Doppler (TD) echocardiographic indices in thalassemia major patients.</p><p><strong>Methods: </strong>A total of 81 TM patients, including 56 females and 25 males, with a mean age of 27.5± 6.8 years, were enrolled consecutively. Serum levels of vitamin D and other biomedical parameters were measured. Then, all patients were subjected to TD echocardiography. Correlations between the serum parameters and systolic and diastolic indices were examined.</p><p><strong>Results: </strong>The serum level of vitamin D was correlated with systolic and diastolic indices such as the EF (r= 0.33, P= 0.003) and TD Imaging (TDI)-lateral (r= 0.31, P= 0.005). However, no correlations were observed between vitamin D deficiency and the LV septal and posterior wall thickness, TDIseptal, tricuspid regurgitation peak gradient (TRPG), pulmonary artery systolic pressure (PASP), deceleration time (DT), and propagation velocity (PVcm/s) indices. The results revealed also no linear correlations between serum vitamin D and albumin (r= -0.17, P= 0.06), ALP (r= -0.12, P= 0.14), T4 (r= -0.11, P= 0.16), as well as TSH (r= -0.10, P= 0.19).</p><p><strong>Conclusion: </strong>It seems that vitamin D deficiency in patients with TM is associated with systolic but not diastolic dysfunctions, possibly as consequences of related biochemical abnormalities.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 3","pages":"214-220"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38106845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
'Do not Do' Recommendations in Hemophilia. 血友病的“不做”建议。
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X20666200305111323
Hortensia De la Corte-Rodriguez, E Carlos Rodriguez-Merchan, M Teresa Alvarez-Roman, Monica Martin-Salces, Victor Jimenez-Yuste

Background: It is important to discard those practices that do not add value. As a result, several initiatives have emerged. All of them try to improve patient safety and the use of health resources.

Purpose: To present a compendium of "do not do recommendations" in the context of hemophilia.

Methods: A review of the literature and current clinical guidelines has been made, based on the best evidence available to date.

Results: The following 13 recommendations stand out: 1) Do not delay the administration of factor after trauma; 2) do not use fresh frozen plasma or cryoprecipitate; 3) do not use desmopressin in case of hematuria; 4) do not change the product in the first 50 prophylaxis exposures; 5) do not interrupt immunotolerance; 6) do not administer aspirin or NSAIDs; 7) do not administer intramuscular injections; 8) do not do routine radiographs of the joint in case of acute hemarthrosis; 9) Do not apply closed casts for fractures; 10) do not discourage the performance of physical activities; 11) do not deny surgery to a patient with an inhibitor; 12) do not perform instrumental deliveries in fetuses with hemophilia; 13) do not use factor IX (FIX) in patients with hemophilia B with inhibitor and a history of anaphylaxis after administration of FIX.

Conclusion: The information mentioned previously can be useful in the management of hemophilia, from different levels of care. As far as we know, this is the first initiative of this type regarding hemophilia.

背景:抛弃那些不能增加价值的实践是很重要的。因此,出现了几项倡议。他们都试图改善病人的安全和卫生资源的使用。目的:在血友病的背景下提出“不做建议”的纲要。方法:回顾文献和目前的临床指南,根据迄今为止最好的证据。结果:突出以下13条建议:1)创伤后不要延误因子的给药;2)不要使用新鲜的冷冻血浆或低温沉淀物;3)血尿时不要使用去氨加压素;4)在前50次预防暴露中不要更换产品;5)不中断免疫耐受;6)不要服用阿司匹林或非甾体抗炎药;7)不要进行肌肉注射;8)急性关节血肿不做关节常规x线片;9)骨折不要使用闭合石膏;10)不妨碍体育活动的进行;11)不拒绝对使用抑制剂的患者进行手术;12)血友病胎儿不要使用器械分娩;13) B型血友病患者在使用FIX后,如果有抑制剂且有过敏史,则不要使用IX因子(FIX)。结论:上述信息可用于血友病的管理,从不同的护理水平。据我们所知,这是针对血友病的首个此类倡议。
{"title":"'Do not Do' Recommendations in Hemophilia.","authors":"Hortensia De la Corte-Rodriguez,&nbsp;E Carlos Rodriguez-Merchan,&nbsp;M Teresa Alvarez-Roman,&nbsp;Monica Martin-Salces,&nbsp;Victor Jimenez-Yuste","doi":"10.2174/1871529X20666200305111323","DOIUrl":"https://doi.org/10.2174/1871529X20666200305111323","url":null,"abstract":"<p><strong>Background: </strong>It is important to discard those practices that do not add value. As a result, several initiatives have emerged. All of them try to improve patient safety and the use of health resources.</p><p><strong>Purpose: </strong>To present a compendium of \"do not do recommendations\" in the context of hemophilia.</p><p><strong>Methods: </strong>A review of the literature and current clinical guidelines has been made, based on the best evidence available to date.</p><p><strong>Results: </strong>The following 13 recommendations stand out: 1) Do not delay the administration of factor after trauma; 2) do not use fresh frozen plasma or cryoprecipitate; 3) do not use desmopressin in case of hematuria; 4) do not change the product in the first 50 prophylaxis exposures; 5) do not interrupt immunotolerance; 6) do not administer aspirin or NSAIDs; 7) do not administer intramuscular injections; 8) do not do routine radiographs of the joint in case of acute hemarthrosis; 9) Do not apply closed casts for fractures; 10) do not discourage the performance of physical activities; 11) do not deny surgery to a patient with an inhibitor; 12) do not perform instrumental deliveries in fetuses with hemophilia; 13) do not use factor IX (FIX) in patients with hemophilia B with inhibitor and a history of anaphylaxis after administration of FIX.</p><p><strong>Conclusion: </strong>The information mentioned previously can be useful in the management of hemophilia, from different levels of care. As far as we know, this is the first initiative of this type regarding hemophilia.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 3","pages":"168-174"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37707696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Fundamentals of Light Chain Cardiac Amyloidosis: A Focused Review. 轻链心脏淀粉样变性的基础:重点综述。
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X20666201130110036
Azka Latif, Noman Lateef, Faryal Razzaq, Vikas Kapoor, Muhammad J Ahsan, Muhammad Ashfaq, Ahmad Iftikhar, Faiz Anwer, Mark Holmberg, Preethi William

The estimated prevalence of AL CA in the US is approximately 8-12 cases per million. Almost 30-50% diagnosed cases of AL amyloid in the US have multisystem involvement, including cardiac involvement. Even with the availability of advanced diagnostic testing and novel therapies, prognosis remains poor. It is overlooked as a cause of heart failure with preserved ejection fraction leading to a delay in diagnosis when management options are limited and associated with poor survival outcomes. Therefore, the education of physicians is needed to ensure that it would be highly considered as a differential diagnosis. The purpose of this manuscript is to review the advances in the diagnosis and management of cardiac amyloidosis with the aim of educating colleagues who provide care in the primary care setting. We have summarized the pathogenesis of amyloidosis, its association with plasma cell dyscrasias, novel diagnostic and surveillance approaches including echocardiography, cardiovascular magnetic resonance imaging, histopathologic techniques, systemic biomarkers, and advanced treatment approaches including supportive symptomatic management and standard of care chemotherapy targeting the amyloid deposits. Given the overall poor prognosis of amyloidosis, we have also discussed the role of palliative and hospice care.

在美国,估计AL - CA的患病率约为每百万人中有8-12例。在美国,近30-50%的AL淀粉样蛋白确诊病例有多系统受累,包括心脏受累。即使有先进的诊断测试和新的治疗方法,预后仍然很差。当管理选择有限且与不良生存结果相关时,它被忽视为保留射血分数的心力衰竭的原因,导致诊断延迟。因此,医生的教育是必要的,以确保它将高度考虑作为鉴别诊断。这篇文章的目的是回顾心脏淀粉样变性的诊断和管理的进展,目的是教育在初级保健环境中提供护理的同事。我们总结了淀粉样变性的发病机制,它与浆细胞异常的关系,新的诊断和监测方法,包括超声心动图,心血管磁共振成像,组织病理学技术,系统生物标志物,先进的治疗方法,包括支持性症状管理和针对淀粉样蛋白沉积的标准护理化疗。鉴于淀粉样变的整体预后不良,我们也讨论了姑息治疗和临终关怀的作用。
{"title":"Fundamentals of Light Chain Cardiac Amyloidosis: A Focused Review.","authors":"Azka Latif,&nbsp;Noman Lateef,&nbsp;Faryal Razzaq,&nbsp;Vikas Kapoor,&nbsp;Muhammad J Ahsan,&nbsp;Muhammad Ashfaq,&nbsp;Ahmad Iftikhar,&nbsp;Faiz Anwer,&nbsp;Mark Holmberg,&nbsp;Preethi William","doi":"10.2174/1871529X20666201130110036","DOIUrl":"https://doi.org/10.2174/1871529X20666201130110036","url":null,"abstract":"<p><p>The estimated prevalence of AL CA in the US is approximately 8-12 cases per million. Almost 30-50% diagnosed cases of AL amyloid in the US have multisystem involvement, including cardiac involvement. Even with the availability of advanced diagnostic testing and novel therapies, prognosis remains poor. It is overlooked as a cause of heart failure with preserved ejection fraction leading to a delay in diagnosis when management options are limited and associated with poor survival outcomes. Therefore, the education of physicians is needed to ensure that it would be highly considered as a differential diagnosis. The purpose of this manuscript is to review the advances in the diagnosis and management of cardiac amyloidosis with the aim of educating colleagues who provide care in the primary care setting. We have summarized the pathogenesis of amyloidosis, its association with plasma cell dyscrasias, novel diagnostic and surveillance approaches including echocardiography, cardiovascular magnetic resonance imaging, histopathologic techniques, systemic biomarkers, and advanced treatment approaches including supportive symptomatic management and standard of care chemotherapy targeting the amyloid deposits. Given the overall poor prognosis of amyloidosis, we have also discussed the role of palliative and hospice care.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 4","pages":"274-283"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38656226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Cardiovascular and Hematological Disorders - Drug Targets
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1